Michael Newman is the founder of Indaptus Therapeutics. Based in New York, United States.
Michael Newman is the Founder and Chief Scientific Officer of Indaptus Therapeutics. The company is a clinical stage biotechnology company focused on developing treatments for cancer and viral infections. Their approach utilizes a Decoy bacterial platform to induce and activate human immune cells, with their lead candidate, Decoy20, designed to trigger broad immune responses.
Full founder directory · Investor directory · Company funding database · Fundraising library